PLoS ONE (Jan 2014)

The mutational spectrum of Lynch syndrome in cyprus.

  • Maria A Loizidou,
  • Ioanna Neophytou,
  • Demetris Papamichael,
  • Panteleimon Kountourakis,
  • Vassilios Vassiliou,
  • Yiola Marcou,
  • Eleni Kakouri,
  • Georgios Ioannidis,
  • Chrystalla Philippou,
  • Elena Spanou,
  • George A Tanteles,
  • Violetta Anastasiadou,
  • Andreas Hadjisavvas,
  • Kyriacos Kyriacou

DOI
https://doi.org/10.1371/journal.pone.0105501
Journal volume & issue
Vol. 9, no. 8
p. e105501

Abstract

Read online

Lynch syndrome is the most common form of hereditary colorectal cancer and is caused by germline mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2. Mutation carriers have an increased lifetime risk of developing colorectal cancer as well as other extracolonic tumours. The aim of the current study was to evaluate the frequency and distribution of mutations in the MLH1, MSH2 and MSH6 genes within a cohort of Cypriot families that fulfilled the revised Bethesda guidelines. The study cohort included 77 patients who fulfilled at least one of the revised Bethesda guidelines. Mutational analysis revealed the presence of 4 pathogenic mutations, 3 in the MLH1 gene and 1 in the MSH2 gene, in 5 unrelated individuals. It is noted that out of the 4 pathogenic mutations detected, one is novel (c.1610delG in exon 14 of the MLH1) and has been detected for the first time in the Cypriot population. Overall, the pathogenic mutation detection rate in our patient cohort was 7%. This percentage is relatively low but could be explained by the fact that the sole criterion for genetic screening was compliance to the revised Bethesda guidelines. Larger numbers of Lynch syndrome families and screening of the two additional predisposition genes, PMS2 and EPCAM, are needed in order to decipher the full spectrum of mutations associated with Lynch syndrome predisposition in Cyprus.